Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- SRRK
- Price
- 27.06
- Stock movement up
- +2.59 (10.58%)
- Company name
- Scholar Rock Holding Corp
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 2.53B
- Ent value
- 2.56B
- Price/Sales
- 217.26
- Price/Book
- 31.99
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -8.79%
- 1 year return
- 86.62%
- 3 year return
- 25.29%
- 5 year return
- 13.42%
- 10 year return
- -
Last updated: 2025-04-10
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
SRRK does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 217.26 |
| Price to Book | 31.99 |
| EV to Sales | 219.28 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 93.61M |
| EPS (TTM) | -2.33 |
| FCF per share (TTM) | -1.95 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 11.66M |
| Gross profit (TTM) | 9.89M |
| Operating income (TTM) | -230.73M |
| Net income (TTM) | -225.97M |
| EPS (TTM) | -2.33 |
| EPS (1y forward) | -2.23 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 84.84% |
| Operating margin (TTM) | -1978.81% |
| Profit margin (TTM) | -1937.96% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 76.39M |
| Net receivables | 1.12M |
| Total current assets | 152.93M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 19.99M |
| Total assets | 179.13M |
| Accounts payable | 4.07M |
| Short/Current long term debt | 66.61M |
| Total current liabilities | 39.37M |
| Total liabilities | 99.94M |
| Shareholder's equity | 79.20M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -188.78M |
| Capital expenditures (TTM) | 76.00K |
| Free cash flow (TTM) | -188.86M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -285.32% |
| Return on Assets | -126.14% |
| Return on Invested Capital | -166.97% |
| Cash Return on Invested Capital | -139.55% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 24.06 |
| Daily high | 27.62 |
| Daily low | 22.71 |
| Daily Volume | 2.12M |
| All-time high | 68.02 |
| 1y analyst estimate | 44.13 |
| Beta | 0.48 |
| EPS (TTM) | -2.33 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 5 May 2025 |
Downside potential
Loading...
Downside potential data
| SRRK | S&P500 | |
| Current price drop from All-time high | -60.22% | -10.49% |
| Highest price drop | -93.15% | -56.47% |
| Date of highest drop | 1 Jun 2022 | 9 Mar 2009 |
| Avg drop from high | -58.78% | -11.07% |
| Avg time to new high | 60 days | 12 days |
| Max time to new high | 1024 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
2.53B
Marketcap category
Mid-cap
Description
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.
Employees
150
Website
Investor relations
-
SEC filings
CEO
Nagesh K. Mahanthappa
Country
USA
City
Cambridge
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page